PMID- 8201385
OWN - NLM
STAT- MEDLINE
DCOM- 19940701
LR  - 20170210
IS  - 0732-183X (Print)
IS  - 0732-183X (Linking)
VI  - 12
IP  - 6
DP  - 1994 Jun
TI  - Allogeneic bone marrow transplantation for children with acute myeloblastic 
      leukemia in first complete remission: impact of conditioning regimen without 
      total-body irradiation--a report from the Societe Francaise de Greffe de Moelle.
PG  - 1217-22
AB  - PURPOSE: To analyze the French experience of chemotherapeutic preparation before 
      human leukocyte antigen (HLA)-identical bone marrow transplantation (BMT) in 
      children with acute myeloblastic leukemia (AML) in first complete remission (CR). 
      PATIENTS AND METHODS: The data base used for this study was a French BMT registry 
      for childhood AML. Twenty-three children were conditioned with busulfan and 120 
      mg/kg cyclophosphamide (Bu-Cy 120 group). Nineteen received busulfan and 200 
      mg/kg cyclophosphamide (Bu-Cy200 group). During the same time period, 32 patients 
      were prepared with total-body irradiation (TBI group) most often in combination 
      with 120 mg/kg of cyclophosphamide. RESULTS: The probability of relapse was 54%, 
      13%, and 10% for the Bu-Cy120, Bu-Cy200, and TBI groups, respectively (P < .05 in 
      the univariate analysis, log-rank test, 2 df). In the multivariate analysis, a 
      conditioning regimen with Bu-Cy120 was significantly associated with a higher 
      risk of relapse (P = .02; relative risk, 3.62). The probability of 
      transplant-related mortality (TRM) was 0% for Bu-Cy120, 5% for Bu-Cy200, and 10% 
      for TBI. Kaplan-Meier estimations of event-free survival (EFS) were 46% +/- 24%, 
      82% +/- 18%, and 80% +/- 14%, respectively, for the three groups, with median 
      follow-up durations of 28 months (range, 3 to 78), 31 months (4 to 68), and 48 
      months (2 to 73). In the multivariate analysis, two factors adversely affected 
      EFS: a conditioning regimen with Bu-Cy120 (P = .07) and a long interval from 
      diagnosis to BMT (> or = 120 days, P = .08). CONCLUSION: Bu-Cy120 is a 
      well-tolerated preparation, but results in a high risk of relapse for children 
      with AML in first CR. This high risk of relapse is not observed when the dose of 
      cyclophosphamide is increased to 200 mg/kg.
FAU - Michel, G
AU  - Michel G
AD  - Service d'Hematologie Pediatrique, Hopital d'enfants La Timone, Marseille, 
      France.
FAU - Gluckman, E
AU  - Gluckman E
FAU - Esperou-Bourdeau, H
AU  - Esperou-Bourdeau H
FAU - Reiffers, J
AU  - Reiffers J
FAU - Pico, J L
AU  - Pico JL
FAU - Bordigoni, P
AU  - Bordigoni P
FAU - Thuret, I
AU  - Thuret I
FAU - Blaise, D
AU  - Blaise D
FAU - Bernaudin, F
AU  - Bernaudin F
FAU - Jouet, J P
AU  - Jouet JP
AU  - et al.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Clin Oncol
JT  - Journal of clinical oncology : official journal of the American Society of 
      Clinical Oncology
JID - 8309333
RN  - 8N3DW7272P (Cyclophosphamide)
RN  - G1LN9045DK (Busulfan)
SB  - IM
MH  - Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
MH  - *Bone Marrow Transplantation
MH  - Busulfan/administration & dosage
MH  - Child
MH  - Child, Preschool
MH  - Combined Modality Therapy
MH  - Cyclophosphamide/administration & dosage
MH  - Female
MH  - Graft vs Host Disease/etiology
MH  - Humans
MH  - Leukemia, Myeloid, Acute/mortality/*therapy
MH  - Male
MH  - Recurrence
MH  - Remission Induction
MH  - Survival Rate
MH  - *Whole-Body Irradiation
EDAT- 1994/06/01 00:00
MHDA- 1994/06/01 00:01
CRDT- 1994/06/01 00:00
PHST- 1994/06/01 00:00 [pubmed]
PHST- 1994/06/01 00:01 [medline]
PHST- 1994/06/01 00:00 [entrez]
AID - 10.1200/JCO.1994.12.6.1217 [doi]
PST - ppublish
SO  - J Clin Oncol. 1994 Jun;12(6):1217-22. doi: 10.1200/JCO.1994.12.6.1217.